Search PubMed⌕ Search

Biomedical subjects

T Kodaira

Publications and source records attributed to T Kodaira.

At least 37 records · Page 2Linked to original sources
PubMed1993

Radioimmunoreactive plasma bradykinin levels and histological changes during the course of cerulein-induced pancreatitis in rats.

The plasma bradykinin (BK) and serum amylase levels and histological changes in rats during the course of acute pancreatitis induced by a large dose of cerulein were examined. Animals were given four intraperitoneal injections of 20 micrograms/kg body wt of cerulein at hourly intervals. The plasma concentration of BK-like immunoreactivity (BK-LI), measured by a highly sensitive and specific radioimmunoassay established in this study, was found to reach a peak 6 h after the first injection of cerulein and then to remain elevated. On the other hand, the serum amylase and the histological alterations (i.e., interstitial edema, vacuolization, and inflammatory infiltration) were maximal 9 h after the first injection and returned to nearly normal after 24 h. These observations suggest that the BK generation is indicative of the participation of the kallikrein-kinin system in the pathophysiological change and that the plasma BK-LI level is a good marker of cellular damage and inflammation within the pancreas during the course of acute pancreatitis.

Acute Disease↗
PubMed1993

Free radical formation induced by ultrasound and its effects on strand breaks in DNA of cultured FM3A cells.

Recent sonochemical studies have revealed that active oxygen species are formed by pyrolysis of water molecules due to high temperature cavitation bubbles. When aqueous solutions of DNA were sonicated, single-strand breaks and double-strand breaks of DNA were observed. Formation of double-strand breaks due to mechanical effects of cavitation and formation of single-strand breaks mostly due to free radicals were indicated. The sonochemically generated radicals from DNA constituents due to H atom and OH radical reactions, and pyrolysis processes, were identified by spin trapping with 3,5-dibromo-2,6-dideuterio-4-nitrosobenzene sulfonate. When suspensions of mouse mammary carcinoma FM3A cells and aqueous solutions of 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) were exposed to 1 MHz ultrasound in the presence of Ar, a good correlation between DMPO-OH formation and the cell killing induced by ultrasound were observed. Although single-strand breaks of DNA in the cells were observed at the maximum intensity of DMPO-OH formation and cell killing, double-strand breaks were not. Free radical formation by ultrasound in aqueous solutions and its relation to DNA strand breaks in vitro and in vivo are discussed.

Animals↗
PubMed1993

Inhibitory effect of intraduodenal infusion of loxiglumide on pancreatic exocrine secretion.

Inhibitory effect of loxiglumide (D,L-4-(3, 4-dichlorobenzoylamino)-5-(N-3-methoxypropyl-pentylamino)-5- oxo-pentanoic acid, CAS 107097-80-3) on exocrine pancreatic secretion was compared between intraduodenal and intravenous administration. Doubling doses of intravenous cholecystokinin octapeptide (CCK-8) resulted in a dose-dependent increase of pancreatic secretion from 50 to 400 ng/kg/h. Both intraduodenal and intravenous loxiglumide of 5 and 10 mg/kg/h produced a dose-dependent inhibition of the pancreatic protein secretion to all doses of CCK-8. Cumulative increment of pancreatic protein output was inhibited by 79% and 77% at 10 mg/kg/h of intraduodenal and intravenous loxiglumide, respectively. Extents of the inhibition were similar to each other between the two routes of loxiglumide infusion. However, plasma levels of loxiglumide after intraduodenal administration were about half of those observed after intravenous administration of the corresponding dose, although plasma CCK levels were not different. Intraduodenal loxiglumide is as effective as intravenous loxiglumide in inhibitory potency on pancreatic secretion. Therefore, possible therapeutic indications of oral loxiglumide could be expected.

Animals↗
PubMed1992

Effect of diltiazem on silent ischemic episodes, plasma bradykinin and prostaglandin metabolism.

Plasma bradykinin and prostaglandin metabolism are related to the anginal pain modulating system in patients with ischemic heart disease. We carried out a placebo controlled single blind test of diltiazem (30 mg three times a day) in 15 patients with chronic stable angina. The effect of diltiazem was evaluated by exercise treadmill testing and 48-h ambulatory electrocardiographic monitoring. Plasma bradykinin, thromboxane B2, and 6-keto-prostaglandin F1 alpha levels were determined by radioimmunoassay prior to and during diltiazem therapy. Diltiazem significantly increased the exercise time and reduced episodes of angina. Diltiazem, however, did not appreciably improve either the frequency of silent myocardial ischemic episodes or the total duration of the silent myocardial ischemic episodes. Diltiazem also tended to decrease plasma bradykinin, thromboxane B2, and 6-keto-prostaglandin F1 alpha levels. When ischemic episodes on ambulatory electrocardiographic monitoring are categorized according to heart rate change at the onset of episode (type A, preceded by heart rate increase > or = 5 beats/min; type B, no preceding heart rate increase), diltiazem was only effective on type A ischemic episodes as well as on symptomatic ischemia. Further, bradykinin was significantly decreased by diltiazem only in patients with exercise-induced silent ischemia or no exercise-induced ischemia, while the thromboxane B2/6-keto-prostaglandin F1 alpha ratio was unaffected by the administration of diltiazem. Thus, silent and symptomatic ischemia may be associated with different bradykinin and prostaglandin responses.

6-Ketoprostaglandin F1 alpha↗
PubMed1990

Stimulatory effects of bombesin on plasma trypsin release and exocrine pancreatic secretion in dogs.

We examined the effect of bombesin on plasma trypsin release and exocrine pancreatic secretion in dogs. Bombesin significantly increased plasma immunoreactive trypsin (IRT). Atropine significantly inhibited the response of plasma IRT to bombesin. Pancreatic trypsin secretion was also increased by bombesin, as well as bicarbonate and protein outputs. Atropine failed to inhibit pancreatic trypsin secretion. In conclusion, bombesin has a stimulatory effect on plasma trypsin release mediated by a cholinergic mechanism and different from pancreatic secretion.

Amylases↗
PubMed1990

Urinary human growth hormone measurement using a highly sensitive sandwich enzyme immunoassay: diagnostic and therapeutic uses in patients with growth hormone deficiency.

Several reports indicate that urinary hGH excretion is significantly lower in patients with either partial (PGHD) or complete GH deficiency (CGHD) than in normal but short children (NSC) or normal children (NC). However, there is an overlap between the NSC and NC groups and the PGHD group. Using a highly sensitive sandwich enzyme immunoassay, we investigated whether the measurement of urinary hGH can clearly separate the PGHD and CGHD groups from the NSC and NC groups. In addition, we measured the urinary excretion of synthetic methionyl-hGH (met-hGH) in PGHD and CGHD after sc injections of 2 and 4 IU and im injections of 4 IU in an attempt to determine the optimal replacement dose. Total 24-h urinary hGH excretion in each patient examined for 2 consecutive days varied from 1 day to the next. There were no differences in urinary hGH excretions between the NSC group and the NC group. The lower values for daily urinary hGH excretion in the NSC group overlapped some of the higher values in the PGHD group. However, when the mean urinary hGH level of both days was used, the 24-h urinary hGH excretion clearly separated the PGHD (5.5 +/- 2.3 ng/day; range, 1.3-9.2; n = 21) and CGHD (1.9 +/- 0.9 ng/day; range, 0.6-3.6; n = 14) groups from the NSC (12.8 +/- 3.1 ng/day; range, 9.3-17.5; n = 10) and NC (14.6 +/- 3.1 ng/day; range, 10.6-19.0; n = 6) groups without any overlap. A mean urinary hGH value less than 9.0 ng/day during a 2-day collection strongly suggested GH deficiency. Ten of 16 patients with PGHD and CGHD who received 2 IU met-hGH, sc, had urinary hGH levels within the range of the mean +/- SD in NSC. These patients received daily sc 0.097 +/- 0.024 IU/kg hGH injections. These results suggest that the measurement of 24-h urinary hGH excretion is noninvasive, accurate, and useful for the screening of GH deficiency. The mean value on 2 days of 24-h urinary hGH excretion for the screening of GH deficiency is estimated to be less than 9.0 ng/day. The optimal dose of GH as therapy for GH deficiency is demonstrated as daily sc injection of 0.1 IU/kg hGH, 0.7 IU/kg/week. To convert international units of met-hGH to milligrams, divide by 2.4.

Child↗
PubMed1990

[The changes of serum gamma-Sm level in acute prostatitis].

gamma-Sm, the specific antigen of the prostate, is useful for the diagnosis and following-up of prostatic cancer. It is recognized as the tumor marker. The serum gamma-Sm is increased in some cases of acute prostatitis. We evaluated the serum gamma-Sm in patients with acute prostatitis. Serum gamma-Sm, PAP, CRP and WBC count were measured before treatment with antibiotics and 3 to 5 days and 1 week thereafter. In the acute phase of inflammation (before treatment) serum gamma-Sm increased in 62.5% of the cases. Then it decreased quickly and was within the normal range 3 to 5 days later. This change of serum gamma-Sm is similar to that of WBC count, fever and urinalysis. But the decrease of serum gamma-Sm is earlier than that of CRP. PAP does not increase in any phase of inflammation. It suggests that the serum gamma-Sm reflects cell damages of the prostatic gland or increased permeability due to prostatitis.

Acute Disease↗
PubMed1988

Meal-stimulated cholecystokinin release and exocrine pancreatic secretion in dogs.

To confirm the role of cholecystokinin (CCK) and secretin in digestion, exocrine pancreatic secretion, plasma CCK, and secretin were measured simultaneously in six dogs prepared with gastric and pancreatic fistulas after feeding a solid meal. Plasma CCK concentration determined by radioimmunoassay increased significantly from the basal level, reached a peak 35 min after meal ingestion, and after a dip it further increased toward the end of the 3-h observation. Pancreatic protein output increased significantly, peaked at the fifth 10-min period, and then declined progressively. Plasma CCK concentration and pancreatic protein output correlated significantly during the first postprandial hour. Plasma secretion demonstrated significant elevation at 15 min and a peak at 25 min after a meal. Plasma secretin correlated significantly with both bicarbonate output and flow rate during the 3 h. Simultaneous measurements of plasma CCK and secretin and of pancreatic secretion suggested that postprandial pancreatic secretion is primarily mediated by releases of CCK and secretin, but these hormones do not seem to be the only factors responsible for the secretion.

Animals↗
PubMed1987

Immunohistochemical demonstration of metallothionein in the rat prostate.

Metallothionein in the rat prostate was demonstrated by using an indirect immunoperoxidase technique. Strong staining was found mainly in the supranuclear area of the cytoplasm of the glandular epithelium in the dorsal and the lateral glands. Diffuse cytoplasmic staining and nuclear staining were found with less frequency. Secretory granules were found in the lumen with various intensities of staining. Most of the epithelial cells in the ventral lobes and the coagulating glands were negatively stained. Immunoreactive cells were found sporadically. Two types of immunoreactive cells, round cells and spindle-shaped cells, were scattered in the stroma. Vascular endothelial cells, red blood cells, and smooth muscle cells were negatively stained. These results suggest the synthesis and secretion of metallothionein in the rat prostate.

Animals↗
PubMed1986

Elevation of plasma CCK concentration after intestinal administration of a pancreatic enzyme secretion-stimulating peptide purified from rat bile-pancreatic juice: analysis with N-terminal region specific radioimmunoassay.

The rat plasma cholecystokinin (CCK) concentration was measured after intestinal administration of a peptide purified from rat bile-pancreatic juice, which has a stimulatory effect on pancreatic enzyme secretion. The plasma CCK concentration was measured by means of a radioimmunoassay using CCK-8 N-terminal specific antibody, OAL-656. In experimental rats with protease-free intestines, intraduodenal infusion of 10 micrograms of the purified peptide, which stimulates pancreatic enzyme secretion 2.0-2.5 fold, induced a significant increase in the plasma CCK level. Furthermore, after removal of CCK from the plasma by immunoabsorption with an OAL-656-bound Sepharose 4B column, the stimulatory effect of the plasma on pancreatic enzyme secretion was abolished when it was injected intravenously into recipient rats. It was concluded that this peptide stimulates the release of CCK in the intestine and that this is responsible at least in part for the pancreatic enzyme secretion-stimulating activity of the peptide.

Animals↗
PubMed1985

A cause of discrepancy between values for urinary protein as assayed by the Coomassie Brilliant Blue G-250 method and the sulfosalicylic acid method.

In simultaneous assays of urinary proteins by the Coomassie Brilliant Blue G-250 (CBB) and the sulfosalicylic acid (SSA) methods, we noticed that about 18% of samples showed about twice higher protein values by the former method than by the latter. Some urinary proteins are soluble in SSA and react with CBB. Examinations with sodium dodecyl sulfate/polyacrylamide gel electrophoresis showed that these proteins migrated in 13 protein bands having relative molecular masses ranging from 15 000 to 230 000. The protein corresponding to the most intensely stained band in urine samples from the patients studied (with malignant tumors, renal disorders, etc.) had an Mr of 45 000; that in the pattern for healthy subjects had an Mr of 94 000. The former was identified as alpha 1-acid glycoprotein, the latter as Tamm-Horsfall mucoprotein.

Benzenesulfonates↗